BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug
Related news
-
Global equities mixed amid rising yields and oil prices
-
Merck's experimental eye drug meets goal in trial, but raises safety concerns
-
Marko Kolanovic calls Trump’s energy ceasefire a ‘con,’ Tom Lee sees potential inflation relief
-
Beta Technologies CEO Kyle Clark sells $612,234 in shares
-
Palo Alto Networks director Bawa sells $103,070 in stock
-
Trump Says Russia And Ukraine Have Reached ‘Energy Ceasefire’— Zelenskyy Reportedly Calls That ‘News For Me’
-
Mineralrite director sells $106.7m preferred shares
-
MediaAlpha CEO Steven Yi sells $263,320 in company stock